Introducing our White Paper: "Bioactive Glass for Lumbar and Cervical Spine Fusion: A Retrospective Case Series." Explore the alternative of NovaBone Collagen Bioglass Bone Graft, a unique biomaterial with osteoconductive properties, through a retrospective analysis of 251 patients.
NovaBone Products, leaders in synthetic biologics, is pleased to announce the company has made commercially available a new syringe for targeted delivery of its 45S5 bioactive glass putty device for the foot and ankle market. The newly launched syringe comes in both a 2.5cc and a 5cc formulation.
ALACHUA, FL June 27, 2023 - NovaBone Products, leaders in synthetic biologics is pleased to announce the company has received clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Wound Matrix product – first of its kind collagen + 45S5 bioactive glass device for the wound care market.
The organization welcomes the New Vice President of Research and Development as they continue building momentum and improving the company’s capabilities.
The organization welcomes the new Vice President of Sales, Orthopedics as they continue building momentum and improving the company’s capabilities.
Leaders in biologic medical devices, NovaBone, has today announced Brian Carlisle as the company’s new CEO. With a focus on developing biomaterials that harness the body’s natural healing process and meeting the specialized needs of orthopedic and dental surgeons, the addition of Mr. Carlisle will play a critical role in the continued growth of the organization.